Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNP-9
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
SNP-9: sourced facts only. name: "Also, calcyclin-binding protein was found to act as a SNP-9-binding protein, by screening of a human brain cDNA library." [PMID:36727262]; target: "Also, calcyclin-binding protein was found to act as a SNP-9-binding protein, by screening of a human brain cDNA library." [PMID:36727262]; developer: "Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China." [PMID:36727262]; stage: "Actions of specific glycine-serine-alanine repeat peptides (SNPs), especially SNP-9, on Alzheimer's disease (AD)-like abnormalities were evaluated in transgenic mice and Caenorhabditis elegans, and in rat and cell models." [PMID:36727262]
02
Targets
CACYBP (Calcyclin-binding protein)
Beyond the preview
Go deeper on SNP-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNP-9.